SCHEMBL5855665

SCHEMBL5855665

COC(=O)CC/C=C/CC(NC(=O)c1ccccc1)C(C)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.54
CTSL P07711 6/20 0.41
CTSS P25774 3/20 0.41
CTSK P43235 3/20 0.41
CTSB P07858 1/20 0.41
GAA P10253 1/20 0.40
CYP1A2 P05177 5/20 0.40
TSHR P16473 4/20 0.40
CYP3A4 P08684 4/20 0.40
ALDH1A1 P00352 4/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5855669 1.00 AKT1 (0.54) AKT1CTSLCTSSCTSKCTSB
SCHEMBL5856845 0.88 TDP1 (0.47) CTSLCTSSCTSKCTSBCYP1A2
SCHEMBL5856849 0.88 TDP1 (0.47) CTSLCTSSCTSKCTSBCYP1A2
SCHEMBL5858345 0.79 PADI1 (0.46) AKT1GAAALDH1A1MEN1KMT2A
SCHEMBL8234372 0.78 GAA (0.55) CTSLCTSSCTSKCTSBGAA
SCHEMBL6048079 0.78 KMT2A (0.47) CTSLCTSSCTSKCTSBGAA
SCHEMBL3485955 0.78 GAA (0.55) CTSLCTSSCTSKCTSBGAA
SCHEMBL8226797 0.78 GAA (0.55) CTSLCTSSCTSKCTSBGAA
SCHEMBL3485952 0.78 GAA (0.55) CTSLCTSSCTSKCTSBGAA
SCHEMBL5857789 0.78 PDE4A (0.45) GAAALDH1A1MEN1KMT2ACRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB AKT1 978/4885CTSL 3295/4885CTSS 3162/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE AKT1 927/4885CTSL 3334/4885CTSS 2866/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC AKT1 684/4885CTSL 3811/4885CTSS 3233/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC AKT1 684/4885CTSL 3811/4885CTSS 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.